【摘要】 肥胖症是一种由遗传、环境等因素引起的以脂肪过多为特征的复杂疾病。retatrutide（研发代号：LY3437943）作为一种胰高血糖素样肽-1/胰高血糖素/葡萄糖依赖性促胰岛素多肽受体激动剂，在肥胖症及心血管疾病治疗中显示出长期有效性。Ⅰ、Ⅱ期临床试验结果表明，retatrutide具有良好的有效性和安全性。该药物目前正在处于Ⅲ期临床试验的招募阶段。本文主要对该药物的基本信息、作用机制、临床前研究及临床研究等方面进行概述。更多还原

【Abstract】 Obesity is a complex disease characterized by excess adiposity caused by genetic and environmental factors.As a glucagon-like peptide-1 receptor/glucagon/glucose-dependent insulinotropic polypeptide receptor agonist, retatrutide(research code:LY3437943) has demonstrated long-term efficacy in the treatments of obesity and cardiovascular disease. The results of phase Ⅰ and Ⅱ clinical trials showed that retatrutide had good efficacy and safety profiles. This drug is currently in the recruitment phase of phase Ⅲ clinical trials. This article provides an overview of the retatrutide’s basic information, mechanism of action, pre-clinical studies and clinical studies.更多还原